This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jun;7(6):315.

doi: 10.1038/nrendo.2011.68. Epub 2011 Apr 19.

Pharmacotherapy: Olmesartan for microalbuminuria--friend or foe?

PMID: 21502981
DOI: 10.1038/nrendo.2011.68

Comment

Pharmacotherapy: Olmesartan for microalbuminuria--friend or foe?

Linda Koch. Nat Rev Endocrinol. 2011 Jun.

. 2011 Jun;7(6):315.

doi: 10.1038/nrendo.2011.68. Epub 2011 Apr 19.

Author

PMID: 21502981
DOI: 10.1038/nrendo.2011.68

No abstract available

PubMed Disclaimer

Comment on

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Haller H, et al. N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994. N Engl J Med. 2011. PMID: 21388309 Clinical Trial.

References

1. N Engl J Med. 2011 Mar 10;364(10):907-17 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.